These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 9713053)

  • 21. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet's Uveitis: A Small Case Series.
    Celiker H; Kazokoglu H; Direskeneli H
    Ocul Immunol Inflamm; 2019; 27(1):15-22. PubMed ID: 28700247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spectrum of Behçet's disease in the Indian population.
    Sachdev N; Kapali N; Singh R; Gupta V; Gupta A
    Int Ophthalmol; 2009 Dec; 29(6):495-501. PubMed ID: 18936879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multifocal ERG changes in patients with ocular Behçet's disease during therapy with interferon alpha 2a.
    Stübiger N; Besch D; Deuter CM; Zierhut M; Kötter I
    Adv Exp Med Biol; 2003; 528():529-32. PubMed ID: 12918757
    [No Abstract]   [Full Text] [Related]  

  • 24. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study.
    Deuter CM; Koetter I; Guenaydin I; Stuebiger N; Zierhut M
    Retina; 2006 Sep; 26(7):786-91. PubMed ID: 16963852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
    Zouboulis CC; Orfanos CE
    Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon alfa-2a in the treatment of Behçet's disease.
    Azizlerli G; Sarica R; Köse A; Ovül C; Kavala M; Kayabali M; Erkan F; Kural Z
    Dermatology; 1996; 192(3):239-41. PubMed ID: 8726638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of interferon α-2a therapy in severe refractory ophthalmic Behcet's disease.
    Kavandi H; Khabbazi A; Kolahi S; Hajialilo M; Shayan FK; Oliaei M
    Clin Rheumatol; 2016 Nov; 35(11):2765-2769. PubMed ID: 27234230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis.
    Plskova J; Greiner K; Forrester JV
    Am J Ophthalmol; 2007 Jul; 144(1):55-61. PubMed ID: 17601428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The use of interferon alfa-2r in the treatment of autoimmune uveitis (primary or associated with Behçet's disease)].
    Sánchez Román J; Pulido Aguilera MC; Castillo Palma MJ; Ocaña Medina C; Toral Peña A; López-Checa F; Wichmann I
    Rev Clin Esp; 1996 May; 196(5):293-8. PubMed ID: 8768028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Panuveitis with oral and genital ulcer misdiagnosed as Behcet's disease: two cases report and literature review].
    Wang Y; Yang L; Zhang ZL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Oct; 48(5):910-914. PubMed ID: 27752180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Ocular manifestations in Behçet's disease].
    Zeghidi H; Saadoun D; Bodaghi B
    Rev Med Interne; 2014 Feb; 35(2):97-102. PubMed ID: 24290834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet's Uveitis: Customizing Therapy according to the Clinical Features.
    De Simone L; Invernizzi A; Aldigeri R; Mastrofilippo V; Marvisi C; Gozzi F; Bolletta E; Adani C; Pipitone N; Muratore F; Fontana L; Salvarani C; Cimino L
    Ocul Immunol Inflamm; 2022 Feb; 30(2):506-514. PubMed ID: 33021421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial.
    Kötter I; Vonthein R; Zierhut M; Eckstein AK; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Stübiger N
    Semin Arthritis Rheum; 2004 Apr; 33(5):311-9. PubMed ID: 15079762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis.
    Onal S; Kazokoglu H; Koc A; Akman M; Bavbek T; Direskeneli H; Yavuz S
    Arch Ophthalmol; 2011 Mar; 129(3):288-94. PubMed ID: 21402983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study.
    Hamuryudan V; Ozyazgan Y; Fresko Y; Mat C; Yurdakul S; Yazici H
    Isr Med Assoc J; 2002 Nov; 4(11 Suppl):928-30. PubMed ID: 12455182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frosted branch angiitis and cerebral venous sinus thrombosis as an initial onset of neuro-Behçet's disease: a case report and review of the literature.
    Ferreira BFA; Rodriguez EEC; Prado LLD; Gonçalves CR; Hirata CE; Yamamoto JH
    J Med Case Rep; 2017 Apr; 11(1):104. PubMed ID: 28410605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years.
    Davatchi F; Sadeghi Abdollahi B; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Faezi T; Akhlaghi M; Ghodsi Z; Ashofteh F; Mohtasham N
    Int J Rheum Dis; 2014 May; 17(4):444-52. PubMed ID: 24314325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macular ischaemia in Behçet's disease.
    Yilmaz G; Akova Y; Aydin P
    Eye (Lond); 2000 Oct; 14 Pt 5():717-20. PubMed ID: 11116691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon therapy for Behçet's disease.
    Alpsoy E; Yilmaz E; Başaran E
    J Am Acad Dermatol; 1994 Oct; 31(4):617-9. PubMed ID: 8089288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
    Sfikakis PP; Theodossiadis PG; Katsiari CG; Kaklamanis P; Markomichelakis NN
    Lancet; 2001 Jul; 358(9278):295-6. PubMed ID: 11498218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.